PAVmed- Warrants (29/01/2022) EBIT

As of the most recent data (March 2026), PAVMW shows a EBIT of $-19B. That compares with $-17B in the prior-year period — down 10.1% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PAVMW's EBIT is now $-19B (was $-17B) — a 10.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PAVmed- Warrants (29/01/2022) is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. PAVmed- Warrants (29/01/2022) is at $-19B, which is lower that average. That is roughly 180.8% below the sector mean. Use the comparison chart on this page to see how PAVMW stacks up against individual peers as well.

Tracking PAVMW's ebit over time shows whether PAVmed- Warrants (29/01/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $-19B That compares with $-17B in the prior-year period — down 10.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has PAVmed- Warrants (29/01/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-19B) with ownership activity and broader fundamentals.